{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:29:14Z","timestamp":1765279754688},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,10,12]],"date-time":"2011-10-12T00:00:00Z","timestamp":1318377600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1471-2407-11-441","type":"journal-article","created":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T20:10:08Z","timestamp":1320178208000},"source":"Crossref","is-referenced-by-count":6,"title":["Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines"],"prefix":"10.1186","volume":"11","author":[{"given":"Rita","family":"\u00d6tv\u00f6s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henriette","family":"Skribek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorand L","family":"Kis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annunziata","family":"Gloghini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laszlo","family":"Markasz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Flaberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Staffan","family":"Eksborg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jozsef","family":"Konya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lajos","family":"Gergely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laszlo","family":"Szekely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,10,12]]},"reference":[{"issue":"1","key":"2928_CR1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2141.2007.06879.x","volume":"140","author":"A Carbone","year":"2008","unstructured":"Carbone A, Gloghini A: KSHV\/HHV8-associated lymphomas. Br J Haematol. 2008, 140 (1): 13-24.","journal-title":"Br J Haematol"},{"issue":"3","key":"2928_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/ajh.10341","volume":"73","author":"E Boulanger","year":"2003","unstructured":"Boulanger E, Daniel MT, Agbalika F, Oksenhendler E: Combined chemotherapy including high-dose methotrexate in KSHV\/HHV8-associated primary effusion lymphoma. Am J Hematol. 2003, 73 (3): 143-148.","journal-title":"Am J Hematol"},{"issue":"3","key":"2928_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/00042560-199611010-00003","volume":"13","author":"KV Komanduri","year":"1996","unstructured":"Komanduri KV, Luce JA, McGrath MS, Herndier BG, Ng VL: The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions. J Acquir Immune Defic Syndr Hum Retrovirol. 1996, 13 (3): 215-226.","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"2","key":"2928_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1148\/radiology.205.2.9356629","volume":"205","author":"S Morassut","year":"1997","unstructured":"Morassut S, Vaccher E, Balestreri L, Gloghini A, Gaidano G, Volpe R, Tirelli U, Carbone A: HIV-associated human herpesvirus 8-positive primary lymphomatous effusions: radiologic findings in six patients. Radiology. 1997, 205 (2): 459-463.","journal-title":"Radiology"},{"issue":"2","key":"2928_CR5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood.V88.2.645.bloodjournal882645","volume":"88","author":"RG Nador","year":"1996","unstructured":"Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM: Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996, 88 (2): 645-656.","journal-title":"Blood"},{"issue":"2","key":"2928_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/ajcp\/105.2.221","volume":"105","author":"MQ Ansari","year":"1996","unstructured":"Ansari MQ, Dawson DB, Nador R, Rutherford C, Schneider NR, Latimer MJ, Picker L, Knowles DM, McKenna RW: Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol. 1996, 105 (2): 221-229.","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"2928_CR7","first-page":"1358","volume":"10","author":"T Otsuki","year":"1996","unstructured":"Otsuki T, Kumar S, Ensoli B, Kingma DW, Yano T, Stetler-Stevenson M, Jaffe ES, Raffeld M: Detection of HHV-8\/KSHV DNA sequences in AIDS-associated extranodal lymphoid malignancies. Leukemia. 1996, 10 (8): 1358-1362.","journal-title":"Leukemia"},{"issue":"7","key":"2928_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0046-8177(97)90153-2","volume":"28","author":"DS Karcher","year":"1997","unstructured":"Karcher DS, Alkan S: Human herpesvirus-8-associated body cavity-based lymphoma in human immunodeficiency virus-infected patients: a unique B-cell neoplasm. Hum Pathol. 1997, 28 (7): 801-808.","journal-title":"Hum Pathol"},{"issue":"18","key":"2928_CR9","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1097\/00002030-199912240-00021","volume":"13","author":"ME Valencia","year":"1999","unstructured":"Valencia ME, Martinez P, Moreno V, Laguna F, Lahoz JG: AIDS-related body cavity-based lymphomas, herpesvirus-8 and HIV infection: a study of seven cases. Aids. 1999, 13 (18): 2603-2605.","journal-title":"Aids"},{"issue":"3","key":"2928_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/sj.thj.6200096","volume":"2","author":"E Boulanger","year":"2001","unstructured":"Boulanger E, Agbalika F, Maarek O, Daniel MT, Grollet L, Molina JM, Sigaux F, Oksenhendler E: A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. Hematol J. 2001, 2 (3): 172-179.","journal-title":"Hematol J"},{"issue":"5","key":"2928_CR11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1634\/theoncologist.12-5-569","volume":"12","author":"YB Chen","year":"2007","unstructured":"Chen YB, Rahemtullah A, Hochberg E: Primary effusion lymphoma. Oncologist. 2007, 12 (5): 569-576.","journal-title":"Oncologist"},{"issue":"12","key":"2928_CR12","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1093\/annonc\/mdl139","volume":"17","author":"TR Halfdanarson","year":"2006","unstructured":"Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M: A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. Ann Oncol. 2006, 17 (12): 1849-1850.","journal-title":"Ann Oncol"},{"issue":"10","key":"2928_CR13","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/sj.leu.2403460","volume":"18","author":"J An","year":"2004","unstructured":"An J, Sun Y, Fisher M, Rettig MB: Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia. 2004, 18 (10): 1699-1704.","journal-title":"Leukemia"},{"issue":"4","key":"2928_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1267\/ahc.05056","volume":"39","author":"E Flaberg","year":"2006","unstructured":"Flaberg E, Stuber G, Szekely L: Multi-dimensional laser confocal microscopy on live cells in submicroliter volumes using glass capillaries. Acta Histochem Cytochem. 2006, 39 (4): 103-106.","journal-title":"Acta Histochem Cytochem"},{"key":"2928_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2342-8-13","volume":"8","author":"E Flaberg","year":"2008","unstructured":"Flaberg E, Sabelstrom P, Strandh C, Szekely L: Extended Field Laser Confocal Microscopy (EFLCM): combining automated Gigapixel image capture with in silico virtual microscopy. BMC Med Imaging. 2008, 8: 13-","journal-title":"BMC Med Imaging"},{"issue":"9","key":"2928_CR16","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1080\/10428190701559132","volume":"48","author":"L Markasz","year":"2007","unstructured":"Markasz L, Kis LL, Stuber G, Flaberg E, Otvos R, Eksborg S, Skribek H, Olah E, Szekely L: Hodgkin-lymphoma-derived cells show high sensitivity to dactinomycin and paclitaxel. Leuk Lymphoma. 2007, 48 (9): 1835-1845.","journal-title":"Leuk Lymphoma"},{"key":"2928_CR17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/1471-2407-6-265","volume":"6","author":"L Markasz","year":"2006","unstructured":"Markasz L, Stuber G, Flaberg E, Jernberg AG, Eksborg S, Olah E, Skribek H, Szekely L: Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells. BMC Cancer. 2006, 6: 265-","journal-title":"BMC Cancer"},{"issue":"12","key":"2928_CR18","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.exphem.2010.09.001","volume":"38","author":"H Skribek","year":"2010","unstructured":"Skribek H, Otvos R, Flaberg E, Nagy N, Markasz L, Eksborg S, Masszi T, Kozma A, Adam E, Miseta A, et al: Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin. Exp Hematol. 2010, 38 (12): 1219-1230.","journal-title":"Exp Hematol"},{"issue":"9","key":"2928_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/bioinformatics\/bth078","volume":"20","author":"MJ de Hoon","year":"2004","unstructured":"de Hoon MJ, Imoto S, Nolan J, Miyano S: Open source clustering software. Bioinformatics. 2004, 20 (9): 1453-1454.","journal-title":"Bioinformatics"},{"issue":"3","key":"2928_CR20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1200\/JCO.1986.4.3.425","volume":"4","author":"RJ Cersosimo","year":"1986","unstructured":"Cersosimo RJ, Hong WK: Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986, 4 (3): 425-439.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2928_CR21","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/cncr.20152","volume":"100","author":"KR Crews","year":"2004","unstructured":"Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, Link MP, Daw NC: High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer. 2004, 100 (8): 1724-1733.","journal-title":"Cancer"},{"issue":"3","key":"2928_CR22","first-page":"653","volume":"4","author":"F Albertioni","year":"1998","unstructured":"Albertioni F, Lindemalm S, Reichelova V, Pettersson B, Eriksson S, Juliusson G, Liliemark J: Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res. 1998, 4 (3): 653-658.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2928_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/BF00256699","volume":"17","author":"MR Hersh","year":"1986","unstructured":"Hersh MR, Kuhn JG, Phillips JL, Clark G, Ludden TM, Von Hoff DD: Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother Pharmacol. 1986, 17 (3): 277-280.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2928_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF00558158","volume":"36","author":"GL Chan","year":"1989","unstructured":"Chan GL, Erdmann GR, Gruber SA, Stock P, Chen S, Ascher NL, Canafax DM: Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine. Eur J Clin Pharmacol. 1989, 36 (3): 265-271.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"2928_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/0145-2126(95)00061-R","volume":"19","author":"A Gruber","year":"1995","unstructured":"Gruber A, Liliemark E, Tidefelt U, Paul C, Bjorkholm M, Peterson C, Liliemark J: Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity. Leuk Res. 1995, 19 (10): 757-761.","journal-title":"Leuk Res"},{"issue":"2","key":"2928_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.phrs.2004.01.006","volume":"50","author":"F Casale","year":"2004","unstructured":"Casale F, Canaparo R, Serpe L, Muntoni E, Pepa CD, Costa M, Mairone L, Zara GP, Fornari G, Eandi M: Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res. 2004, 50 (2): 173-179.","journal-title":"Pharmacol Res"},{"issue":"6","key":"2928_CR27","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/annonc\/mdf164","volume":"13","author":"S Fogli","year":"2002","unstructured":"Fogli S, Danesi R, Gennari A, Donati S, Conte PF, Del Tacca M: Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Ann Oncol. 2002, 13 (6): 919-927.","journal-title":"Ann Oncol"},{"key":"2928_CR28","unstructured":"GlaxoSmithKline Research Triangle Park N: Prescribing Information Leukeran\u00ae. [ http:\/\/www.drugs.com\/monograph\/leukeran.html ]"},{"issue":"5","key":"2928_CR29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s002800050408","volume":"37","author":"S Ghazal-Aswad","year":"1996","unstructured":"Ghazal-Aswad S, Calvert AH, Newell DR: A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol. 1996, 37 (5): 429-434.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2928_CR30","first-page":"1205","volume":"6","author":"MA Graham","year":"2000","unstructured":"Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E: Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000, 6 (4): 1205-1218.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2928_CR31","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/annonc\/mdf305","volume":"13","author":"D Rischin","year":"2002","unstructured":"Rischin D, Ackland SP, Smith J, Garg MB, Clarke S, Millward MJ, Toner GC, Zalcberg J: Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics. Ann Oncol. 2002, 13 (11): 1810-1818.","journal-title":"Ann Oncol"},{"issue":"14","key":"2928_CR32","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-0829-03","volume":"10","author":"SE Bates","year":"2004","unstructured":"Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, et al: A phase I\/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res. 2004, 10 (14): 4724-4733.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2928_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/BF00255486","volume":"8","author":"ZR Desai","year":"1982","unstructured":"Desai ZR, Van den Berg HW, Bridges JM, Shanks RG: Can severe vincristine neurotoxicity be prevented?. Cancer Chemother Pharmacol. 1982, 8 (2): 211-214.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2928_CR34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1200\/jco.2003.09.057","volume":"21","author":"G Freyer","year":"2003","unstructured":"Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K, Trillet-Lenoir V: Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 2003, 21 (1): 35-40.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2928_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF00253099","volume":"2","author":"B Andersson","year":"1979","unstructured":"Andersson B, Andersson I, Beran M, Ehrsson H, Eksborg S: Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex. Cancer Chemother Pharmacol. 1979, 2 (1): 15-17.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"2928_CR36","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1093\/annonc\/mdh464","volume":"15","author":"G Toffoli","year":"2004","unstructured":"Toffoli G, Corona G, Cattarossi G, Boiocchi M, Di Gennaro G, Tirelli U, Vaccher E: Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Ann Oncol. 2004, 15 (12): 1805-1809.","journal-title":"Ann Oncol"},{"issue":"16","key":"2928_CR37","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1158\/1078-0432.CCR-04-2546","volume":"11","author":"GJ Veal","year":"2005","unstructured":"Veal GJ, Cole M, Errington J, Parry A, Hale J, Pearson AD, Howe K, Chisholm JC, Beane C, Brennan B, et al: Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clin Cancer Res. 2005, 11 (16): 5893-5899.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2928_CR38","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/bjc.1980.110","volume":"41","author":"YM Peng","year":"1980","unstructured":"Peng YM, Alberts DS, Chen HS, Mason N, Moon TE: Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration. Br J Cancer. 1980, 41 (4): 644-647.","journal-title":"Br J Cancer"},{"issue":"4","key":"2928_CR39","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/1097-0142(20010215)91:4<815::AID-CNCR1069>3.0.CO;2-J","volume":"91","author":"P Kozuch","year":"2001","unstructured":"Kozuch P, Hoff PM, Hess K, Adams J, Newman RA, Lee F, Pazdur R: Phase I bioequivalency study of MitoExtra and mitomycin C in patients with solid tumors. Cancer. 2001, 91 (4): 815-821.","journal-title":"Cancer"},{"issue":"4","key":"2928_CR40","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1177\/0091270004273526","volume":"45","author":"JH Yan","year":"2005","unstructured":"Yan JH, Ataga K, Kaul S, Olson JS, Grasela DM, Gothelf S, Kutlar A, Orringer E: The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. J Clin Pharmacol. 2005, 45 (4): 434-445.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"2928_CR41","first-page":"69","volume":"5","author":"CJ Gerrits","year":"1999","unstructured":"Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, et al: A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res. 1999, 5 (1): 69-75.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2928_CR42","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/00007691-200208000-00007","volume":"24","author":"P Ylikangas","year":"2002","unstructured":"Ylikangas P, Mononen I: Serious neutropenia in ALL patients treated with L-asparaginase may be avoided by therapeutic monitoring of the enzyme activity in the circulation. Ther Drug Monit. 2002, 24 (4): 502-506.","journal-title":"Ther Drug Monit"},{"issue":"11","key":"2928_CR43","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","volume":"22","author":"CN Papandreou","year":"2004","unstructured":"Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, et al: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004, 22 (11): 2108-2121.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2928_CR44","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/01.qai.0000187444.38461.70","volume":"40","author":"SR Penzak","year":"2005","unstructured":"Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J: Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. J Acquir Immune Defic Syndr. 2005, 40 (5): 573-580.","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-441.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-11-441\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T08:25:35Z","timestamp":1713083135000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-11-441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["2928"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-11-441","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,12]]},"article-number":"441"}}